ERBB2 and gastroesophageal junction adenocarcinoma: This was based on DESTINY-Gastric01, a multicenter, randomized trial of patients with HER2-positive locally advanced, metastatic gastric, or GEJ adenocarcinoma, and who progressed on at least two prior regimens.